Potassium Iodide
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Potassium Iodide: From an Undocumented Original Indication to Nasal Cavity Disease
One-Sentence Summary
Potassium iodide (DB06715) does not currently have a documented original indication or mechanism of action in the available dataset. The TxGNN model predicts it may be effective for Nasal Cavity Disease, but this is currently supported only by 4 case-report-level publications and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no license or indication data in current dataset |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 (mechanism/case-report level, no clinical trials) |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for potassium iodide is not currently available in this dataset. Based on the supporting literature, potassium iodide (KI) has known antifungal and immunomodulatory properties, and has long been used clinically as a traditional treatment for cutaneous fungal infections such as sporotrichosis.
The identified case reports show that KI has been used — with apparent benefit — to treat fungal infections of the nasal cavity, including nasofacial zygomycosis, mycotic rhinitis (Aspergillus fumigatus), and pythiosis. The proposed mechanism relates to KI’s antifungal activity and its ability to promote inflammatory clearance of the causative pathogen. However, this evidence base primarily supports a much narrower indication — fungal infection of the nasal cavity — rather than the broad TxGNN-predicted category of “nasal cavity disease.” The mismatch between the granularity of the supporting evidence and the breadth of the predicted indication is an important limitation to note.
Because the drug’s original indication and MOA are undocumented in this dataset, the mechanistic rationale above should be treated as literature-derived context rather than a confirmed pharmacological pathway from original to new indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7997795 | 1994 | Case Report (Human) | Rev Inst Med Trop Sao Paulo | Rapid clinical response to potassium iodide therapy in a case of nasofacial zygomycosis affecting the nasal cavity mucosa |
| 34902797 | 2022 | Case Report (Veterinary) | Journal de mycologie médicale | Successful potassium iodide treatment of rhinofacial pythiosis (Pythium insidiosum) causing nasal cavity masses in sheep |
| 39576399 | 2024 | Case Report (Veterinary) | Veterinary Research Communications | Oral potassium iodide combined with topical clotrimazole used to treat Aspergillus fumigatus mycotic rhinitis in a horse |
| 10976304 | 2000 | Case Report (Veterinary) | J Am Vet Med Assoc | Sodium/potassium iodide used adjunctively with intranasal miconazole for Pseudallescheria boydii nasal cavity infection in a horse |
US Market Information
Potassium iodide (DB06715) is currently not marketed in this dataset’s regulatory scope, with 0 licenses on record. No product/dosage-form or approved-indication information is available for tabulation.
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug interaction data are not currently available for this candidate; TFDA label warnings/contraindications are flagged as a blocking data gap.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting the “nasal cavity disease” indication is currently limited to four veterinary/human case reports (L4), with no clinical trials and no confirmed mechanistic link beyond a narrower fungal-infection context. Critical safety data (TFDA warnings/contraindications) and the drug’s original indication/MOA are also missing, blocking any safety pre-assessment (S1).
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — currently a blocking data gap
- Confirmation of potassium iodide’s original approved indication(s) and MOA (via DrugBank or equivalent)
- Clarification of whether the predicted indication should be narrowed to “fungal nasal cavity infection” to better match the underlying evidence
- Formal clinical evidence (even observational/case-series) specific to nasal cavity disease before advancing beyond Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.